TY - JOUR T1 - Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden JO - Cardiology and Therapy UR - http://eprints.whiterose.ac.uk/115425/ PY - 2015/12/01 AU - Begum N AU - Stephens S AU - Schoeman O AU - Fraschke A AU - Kirsch B AU - Briere J-B AU - Verheugt FWA AU - van Hout BA ED - DO - DOI: 10.1007/s40119-015-0041-3 VL - 4 IS - 2 SP - 131 EP - 153 Y2 - 2025/05/18 ER -